Tolerability of ALK Grass Tablet in Children

ALK-Abelló

Status and phase: Completed; Phase 1

Conditions: Allergy

Treatments: Biological: ALK Grass tablet

Study type: Interventional

Funder types: Industry

Identifiers

NCT00310453

GT-09

Details and patient eligibility

About

The purpose of this trial is to assess whether the ALK Grass tablet treatment is safe to use in children aged 5-12 years

Sex: All

Ages: 5 to 12 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Grass pollen induced rhinoconjunctivitis
• Boys and girls, 5-12 years of age
• Positive skin prick test to grass pollen

Exclusion criteria

• Severe asthma
• Previous treatment with immunotherapy